You are viewing the 1st of the 2 courses UPMC Physician Resources permits you to view without registering. To have full access to our FREE courses on our website, please register or log in now.

Drs.Lisa Butterfield, and Nathan Bahary each present at the 2017 UPCI GI Oncology Symposium.  Dr. Butterfield discusses immunotherapy for Hepatocelluar cancer. And, Dr. Behary discusses the past, present and future for immunotherapy of colorectal cancer.

Educational objectives:

Upon completion of this activity, participants should be able to:

  • Recognize immune-based therapeutic approaches for hepatocellular cancer
  • Recognize that patient responses to immune therapies and patient immune function in HCC is highly variable
  • Identify immune dysfunction that may be mediated by AFP secreted by HCC tumors
  • Recognize microsatellite instability
  • Recognize the predictive and prognostic implications of the different mechanisms of harboring a microsatellite unstable CRC (colorectal tumors)
  • Recognize the role for immune therapies in treating patients with dMMR (MSI-H) CRC

Reading Resources:

  1. Pardee, A.D., Shi, J., and Butterfield, L.H.  Tumor-derived alpha-fetoprotein impairs the differentiation and T cell stimulatory activity of human dendritic cells. J Immunol. 2014 Dec 1;193(11):5723-32. doi: 10.4049/jimmunol.1400725. Epub 2014 Oct 29.  PMID:25355916; PMCID: PMC4239186
  2. . Butterfield, L.H.  Cancer vaccines.  BMJ. 2015 Apr 22;350:h988. doi: 0.1136/bmj.h988. PMID:25904595
  3. . Forner A, Llovet JM, Bruix J. 2012. Hepatocellular carcinoma. Lancet 379(9822):1245-55. doi: 10.1016/S0140-6736(11)61347-0. PubMed PMID: 22353262.
  4. Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., et al. (2015). PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. The New England Journal of Medicine, 372(26), 2509–2520.
  5. Llosa, N. J., Cruise, M., Tam, A., Wicks, E. C., Hechenbleikner, E. M., Taube, J. M., et al. (2015). The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discovery, 5(1), 43–51.
  6. Xiao, Y., & Freeman, G. J. (2015). The microsatellite instable subset of colorectal cancer is a particularly good candidate for checkpoint blockade immunotherapy. Cancer Discovery, 5(1), 16–18.
  7. Boutros, C., Tarhini, A., Routier, E., Lambotte, O., Ladurie, F. L., Carbonnel, F., et al. (2016). Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nature Reviews. Clinical Oncology, 13(8), 473–486.
  8. Pfirschke, C., Engblom, C., Rickelt, S., Cortez-Retamozo, V., Garris, C., Pucci, F., et al. (2016). Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy. Immunity, 44(2), 343–354.
  9. Weber, J. S., Yang, J. C., Atkins, M. B., & Disis, M. L. (2015). Toxicities of Immunotherapy for the Practitioner. Journal of Clinical Oncology, 33(18), 2092–2099.
  10. de Rosa, N., Rodriguez-Bigas, M. A., Chang, G. J., Veerapong, J., Borras, E., Krishnan, S., et al. (2016). DNA Mismatch Repair Deficiency in Rectal Cancer: Benchmarking Its Impact on Prognosis, Neoadjuvant Response Prediction, and Clinical Cancer Genetics. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 34(25), 3039–3046.
  11. Stadler, Z. K., Battaglin, F., Middha, S., Hechtman, J. F., Tran, C., Cercek, A., et al. (2016). Reliable Detection of Mismatch Repair Deficiency in Colorectal Cancers Using Mutational Load in Next-Generation Sequencing Panels. Journal of Clinical Oncology, 34(18), 2141–2147.
  12. Hartman, D. J., Brand, R. E., Hu, H., Bahary, N., Dudley, B., Chiosea, S. I., et al. (2013). Lynch syndrome-associated colorectal carcinoma: frequent involvement of the left colon and rectum and late-onset presentation supports a universal screening approach. Human Pathology, 44(11), 2518–2528.
  13. Stadler, Z. K., Battaglin, F., Middha, S., Hechtman, J. F., Tran, C., Cercek, A., et al. (2016). Reliable Detection of Mismatch Repair Deficiency in Colorectal Cancers Using Mutational Load in Next-Generation Sequencing Panels. Journal of Clinical Oncology, 34(18), 2141–2147.


Dr. Butterfield  has financial interests with the following any entity or entities producing health care goods or services as indicated below:

  • Consultant: AstraZeneca, Verastem, Immune Design, Kite Pharma
  • Stockholder: Kite Pharma, Simpatica

Dr. Bahary has reported no relevant relationships with any entities producing health care goods or services

All presenters disclosure of relevant financial relationships with any entity producing, marketing, re-selling, or distributing health care goods or services, used on, or consumed by, patients is listed above.  No other planners, members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships to disclose.

Accreditation Statement:

The University of Pittsburgh School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Pittsburgh School of Medicine designates this enduring material for a maximum of .75 AMA PRA Category 1 Credits™. Each physician should only claim credit commensurate with the extent of their participation in the activity. Other health care professionals are awarded (0.075) continuing education units (CEU) which are equivalent to 1 contact hour.

For your credit transcript, please access our website 4 weeks post-completion at and follow the link to the Credit Transcript page. If you do not provide the last 5 digits of your SSN on the next page you will not be able to access a CME credit transcript. Providing your SSN is voluntary.

Release Date: 10/26/2017 | Last Modified On: 10/26/2017 | Expires: 10/26/2018

take cme evaluation